Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) PT at $40.38

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has received an average recommendation of "Buy" from the ten brokerages that are covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $40.38.

Several brokerages have issued reports on ORKA. Wolfe Research began coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 target price on the stock. Wedbush restated an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research note on Thursday, May 15th. Wall Street Zen upgraded Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. HC Wainwright restated a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Finally, BTIG Research began coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They issued a "buy" rating on the stock.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds have recently bought and sold shares of ORKA. FMR LLC boosted its holdings in Oruka Therapeutics by 17.7% in the 4th quarter. FMR LLC now owns 5,512,300 shares of the company's stock valued at $106,883,000 after purchasing an additional 830,000 shares during the period. Fairmount Funds Management LLC increased its holdings in shares of Oruka Therapeutics by 5.0% in the fourth quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company's stock worth $65,382,000 after purchasing an additional 160,000 shares during the period. VR Adviser LLC increased its holdings in shares of Oruka Therapeutics by 6.5% in the fourth quarter. VR Adviser LLC now owns 3,285,620 shares of the company's stock worth $63,708,000 after purchasing an additional 200,000 shares during the period. RTW Investments LP increased its holdings in shares of Oruka Therapeutics by 5.1% in the fourth quarter. RTW Investments LP now owns 1,945,649 shares of the company's stock worth $37,726,000 after purchasing an additional 95,001 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after purchasing an additional 1,572,853 shares during the period. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Stock Up 0.3%

Oruka Therapeutics stock traded up $0.03 during mid-day trading on Monday, reaching $11.47. 123,010 shares of the company's stock were exchanged, compared to its average volume of 225,159. The business's fifty day simple moving average is $9.77 and its 200 day simple moving average is $13.99. The firm has a market capitalization of $429.45 million, a PE ratio of -1.83 and a beta of 0.25. Oruka Therapeutics has a one year low of $5.49 and a one year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.17. On average, sell-side analysts forecast that Oruka Therapeutics will post -3.41 earnings per share for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.